Comparison of Pain Levels in Fusion Prostate Biopsy and Standard TRUS-Guided Biopsy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03859804 |
Recruitment Status :
Completed
First Posted : March 1, 2019
Last Update Posted : March 1, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pain Due to Certain Specified Procedures Prostate Cancer Biopsy | Procedure: Standard transrectal 12 core biopsy Procedure: MRI- US fusion prostate biopsy (FPB) | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 252 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | pain levels after standard transrectal prostate 12 core biopsy and MRI -US fusion prostate biopsy were detected and compared in 2 groups. |
Masking: | None (Open Label) |
Primary Purpose: | Supportive Care |
Official Title: | Comparison of Pain Levels in Fusion Prostate Biopsy and Standard TRUS-Guided Biopsy |
Actual Study Start Date : | December 1, 2016 |
Actual Primary Completion Date : | January 31, 2019 |
Actual Study Completion Date : | February 1, 2019 |

Arm | Intervention/treatment |
---|---|
Experimental: Group 1
In Group 1, Patients detected with a PI-RADS (Prostate Imaging Reporting and Data System) ≥3 lesion on MpMRI underwent MpMRI-guided MRI- US fusion prostate biopsy. In this fusion biopsy, 12 core standard biopsy and 2-4 cores of biopsies from lesions defined on multiparametric prostate MRI
|
Procedure: MRI- US fusion prostate biopsy (FPB)
FPB was performed by obtaining 10-12 core samples in each patient, followed by the acquisition of 2-4 core samples for each suspected lesion detected on MpMRI (combined biopsy)
Other Name: Group 1 |
Active Comparator: Group 2
In Group 2, patients who had no suspected lesions or had a PI-RADS <3 lesion on MpMRI underwent Transrectal ultrasound guided 12 core prostate biopsy (SPB).
|
Procedure: Standard transrectal 12 core biopsy
TRUS-guided SPB was performed by obtaining 12 core samples in each patient. 6 cores from left and right. the cores labeled as, apex, mid, base, apex far lateral, mid far lateral and base far lateral
Other Name: Group 2 |
- To detect painful steps of biopsy procedure by asking patients verbally [ Time Frame: Within 5 minutes after biopsy ]to ask patients most painful step of procedure that verbally defined them before biopsy as 1: insertion of the probe into the rectum, 2: probe manipulation, and 3: the piercing of the biopsy needle
- Over all Visual analogue Score (VAS) score of procedure(From 0 to 100 points, 100 is max pain score according to patient) [ Time Frame: Within 5 minutes after prostate biopsy ]pain assessment was performed using Visual Analogue Scale (VAS)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 50 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Elevated blood prostate specific antigen (PSA) levels according to patients age. PSA >2ng/ml for whom aged between 50-60, and PSA >4ng/ml for whom were above 60 years old
- Having suspicious digital rectal examination
- having multi-parametric prostate MRI before prostate biopsy
- Having MRI defined lesions which were PIRADS - 3 -4-5
Exclusion Criteria:
- PSA > 50 ng/ml
- previous negative biopsy
- neurological disorders that could affect the pain level such as paraplegia or hemiplegia, analgesics use for any reason on the day of or the day before the procedure,
- patients underwent biopsy under general anesthesia,
- having such diseases as anal fissure or hemorrhoidal disease that could alter the pain threshold

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03859804
Turkey | |
Department of Urology, Ercieys University, Faculty Of Medicine, | |
Kayseri, Turkey, 38039 |
Principal Investigator: | Abdullah T Demirtaş, MD | Erciyes University Faculty of Medicine Department of Urolgoy |
Other Publications:
Responsible Party: | Abdullah Demirtas, Abdullah Demirtas, Md, Assoc. Prof., TC Erciyes University |
ClinicalTrials.gov Identifier: | NCT03859804 |
Other Study ID Numbers: |
2014/508 |
First Posted: | March 1, 2019 Key Record Dates |
Last Update Posted: | March 1, 2019 |
Last Verified: | February 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
fusion prostate biopsy pain |
Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms |
Neoplasms by Site Neoplasms Prostatic Diseases |